From the publishers of JADPRO

Biomarkers in NSCLC Resource Center

Advertisement

FDA Approves Neoadjuvant Nivolumab and Platinum Doublet Chemotherapy for Early-Stage NSCLC

On March 4, the FDA approved nivolumab in combination with platinum-doublet chemotherapy for adult patients with resectable non–small cell lung cancer (NSCLC) in the neoadjuvant setting. This represents the first FDA approval for neoadjuvant therapy for early-stage NSCLC.

 

The ASCO Post
Advertisement
News & Literature Highlights
Advertisement
Advertisement